Chiesi: latest news - GoINPHARMA
Friday, 21 September 2018 - 1:29

Chiesi

Chiesi acquires Marco Antonetto and Laevolac brand from Roche

Chiesi Farmaceutici yesterday announced it has acquired the Laevolac  brand from Roche and the Marco Antonetto company with its product portfolio. The move will strengthen Chiesi’s position in the OTC business and will grant it access to the gastrointestinal treatments…

Chiesi signs $370m-worth license agreement with Protalix

Israel-based Protalix Biotherapeutics today announced it has signed a license agreement worth $370m with Chiesi Farmaceutici over pegunigalsidase alfa (PRX-102). Under the agreement, Protalix will sell Chiesi the the worldwide, Ex-US commercialization rights to PRX-102, and will receive $25m upfront,…

An analysis of Italian multinational Menarini

Milano Finanza has published a long article about the Italy-based multinational Menarini, which has grown at higher rates than the pharmaceutical industry’s average over the last years. The group, controlled by the holding company Pharmafin, which belongs to the Aleotti…

Horizon Pharma sells rights to two drugs to Chiesi for $70m

Dublin-based Horizon Pharma sold the rights to PROCYSBI (cysteamine bitartrate) and QUINSAIR (levofloxacin inhalation solution) in the EMEA regions to Chiesi Farmaceutici S.p.A. for $70m, with additional potential payments based on achievement of precise milestones. Horizon’s facilities in the Netherlands,…

Chiesi exploring new acquisitions in Italy and abroad

Italy-based pharmaceutical group Chiesi Farmaceutici is reportedly assessing acquisition targets both in Italy and abroad, Alberto Chiesi, chairman of the group, announced. Chiesi confirmed that the company will continue carrying out acquisitions in the coming years and took the opportunity…

Chiesi, Marco Antonetto sign deal

Italian daily Il Corriere della Sera reported that Turin, Italy-based Marco Antonetto Farmaceutici is likely to be acquired by Chiesi Farmaceutici. The parties are reported to have already signed a distribution agreement likely to evolve into an acquisition. The agreement…

Chiesi/Aptuit deal for idiopathic pulmonary fibrosis treatment

Aptuit and Chiesi Farmaceutici announced they have entered into an agreement under which Aptuit will conduct a Discovery Project aimed at providing innovative drugs to treat idiopathic pulmonary fibrosis. Both Aptuit and Chiesi will contribute scientifically. Atpuit sold its clinical…

Chiesi focuses on M&A again: Atopix Therapeutics acquired for €75m

Chiesi Farmaceutici announced today that it has acquired UK-based Atopix Therapeutics Limited for €75m. A part of the amount is subject to the achievement of precise regulatory and commercial milestones—should these exceed the set targets, the company value could even…

Chiesi fixed triple combination, positive results from two studies on COPD

The results from the TRILOGY study, designed to assess the extrafine fixed ICS/LABA/LAMA triple combination (beclomethasone/formoterol/glycopyrronium) developed by Chiesi, already published on the prestigious journal The Lancet, will be presented at the ERS (European Respiratory Society) Congress. The study demonstrates…